1. 3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM). (September 2015) Authors: Gregorc, V.; Gaafar, R.; Favaretto, A.; Grossi, F.; Jassem, J.; Polychronis, A.; Bidoli, P.; Tiseo, M.; O'Brien, M.; Shah, R.; Taylor, P.; Novello, S.; Muzio, A.; Bearz, A.; Badurak, P.; Greillier, L.; Fontana, F.; Colombi, S.; Lambiase, A.; Bordignon, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗